HomeCompareEPGNY vs GBDC

EPGNY vs GBDC: Dividend Comparison 2026

EPGNY yields 113.84% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $14.02M in total portfolio value· pulled ahead in Year 9
10 years
EPGNY
EPGNY
● Live price
113.84%
Share price
$2.39
Annual div
$2.72
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.75M
Annual income
$2,475,584.99
Full EPGNY calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — EPGNY vs GBDC

📍 GBDC pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPGNYGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPGNY + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPGNY pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPGNY
Annual income on $10K today (after 15% tax)
$9,676.26/yr
After 10yr DRIP, annual income (after tax)
$2,104,247.24/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $11,826,626.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPGNY + GBDC for your $10,000?

EPGNY: 50%GBDC: 50%
100% GBDC50/50100% EPGNY
Portfolio after 10yr
$13.76M
Annual income
$9,432,424.20/yr
Blended yield
68.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

EPGNY
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPGNY buys
0
GBDC buys
0
No recent congressional trades found for EPGNY or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPGNYGBDC
Forward yield113.84%11.85%
Annual dividend / share$2.72$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$6.75M$20.78M
Annual income after 10y$2,475,584.99$16,389,263.41
Total dividends collected$6.11M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: EPGNY vs GBDC ($10,000, DRIP)

YearEPGNY PortfolioEPGNY Income/yrGBDC PortfolioGBDC Income/yrGap
1$22,084$11,383.83$12,490$1,790.28+$9.6KEPGNY
2$47,125$23,495.20$16,522$3,157.73+$30.6KEPGNY
3$97,280$46,856.67$23,578$5,898.68+$73.7KEPGNY
4$194,489$90,398.69$37,115$11,886.75+$157.4KEPGNY
5$377,010$168,906.98$66,136$26,423.57+$310.9KEPGNY
6$709,401$306,000.59$137,257$66,491.44+$572.1KEPGNY
7$1,297,177$538,118.21$341,734$194,868.54+$955.4KEPGNY
8$2,307,585$919,605.21$1,050,788$685,133.02+$1.26MEPGNY
9← crossover$3,998,005$1,528,889.11$4,099,314$2,974,971.01$101.3KGBDC
10$6,753,450$2,475,584.99$20,775,530$16,389,263.41$14.02MGBDC

EPGNY vs GBDC: Complete Analysis 2026

EPGNYStock

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Full EPGNY Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this EPGNY vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPGNY vs SCHDEPGNY vs JEPIEPGNY vs OEPGNY vs KOEPGNY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.